These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1674161)

  • 61. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
    Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
    Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
    Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
    Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research (author's transl)].
    Mattke DJ; Mombour W; Glötzner FL
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Jan; 8(1):36-44. PubMed ID: 788001
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 66. Early clinical results with the neuroleptic roxindole (EMD 49,980) in the treatment of schizophrenia--an open study.
    Kasper S; Fuger J; Zinner HJ; Bäuml J; Möller HJ
    Eur Neuropsychopharmacol; 1992 Mar; 2(1):91-5. PubMed ID: 1353388
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Direct microtitre plate radioimmunoassay of savoxepine in unextracted plasma.
    Lefèvre G; Duval M; Botta L; Godbillon J
    J Immunoassay; 1996 Feb; 17(1):29-46. PubMed ID: 8926305
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Loxapine succinate as initial treatment of hostile and aggressive schizophrenic criminal offenders.
    Feldman HS
    J Clin Pharmacol; 1982; 22(8-9):366-70. PubMed ID: 7130427
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone.
    Ceulemans DL; Gelders YG; Hoppenbrouwers ML; Reyntjens AJ; Janssen PA
    Psychopharmacology (Berl); 1985; 85(3):329-32. PubMed ID: 3923519
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Perazine for schizophrenia.
    Leucht S; Helfer B; Hartung B
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD002832. PubMed ID: 24425538
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adverse effects of antipsychotic agents. Do newer agents offer advantages?
    Owens DG
    Drugs; 1996 Jun; 51(6):895-930. PubMed ID: 8736614
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET).
    Leenders KL; Antonini A; Thomann R; Locher JT; Maître L; Gerebtzoff A; Beer HF; Ametamey S; Weinreich R; Gut A
    Eur J Clin Pharmacol; 1993; 44(2):135-40. PubMed ID: 8095895
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Savoxepine fails to selectively influence glucose metabolism in the rat limbic system.
    Cascella NG; Tarazi FI; Shirakawa O; Tamminga CA
    Psychopharmacology (Berl); 1994 Mar; 114(2):275-80. PubMed ID: 7838920
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters.
    Wetzel H; Szegedi A; Hain C; Wiesner J; Schlegel S; Benkert O
    Psychopharmacology (Berl); 1995 May; 119(2):231-8. PubMed ID: 7659771
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability.
    Hoffman DC; Donovan H
    Psychopharmacology (Berl); 1995 Jul; 120(2):128-33. PubMed ID: 7480543
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients.
    Wetzel H; Wiedemann K; Holsboer F; Benkert O
    Psychopharmacology (Berl); 1991; 103(2):280-3. PubMed ID: 1674161
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study.
    Möller HJ; Kissling W; Dietzfelbinger T; Stoll KD; Wendt G
    Pharmacopsychiatry; 1989 Jan; 22(1):38-41. PubMed ID: 2565583
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
    Butler B; Bech P
    Pharmacopsychiatry; 1987 May; 20(3):122-6. PubMed ID: 2885867
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia.
    Volz HP; Möller HJ; Gerebtzoff A; Bischoff S
    Eur Arch Psychiatry Clin Neurosci; 2002 Apr; 252(2):76-80. PubMed ID: 12111340
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine.
    Herrmann WM; Schärer E; Delini-Stula A
    Pharmacopsychiatry; 1991 Nov; 24(6):196-205. PubMed ID: 1687485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.